[1]CurrentPatentAssignee:HISUNGROUPCO.,LTD.-CN106432077,2017,ALocationinpatent:Paragraph0017;0071-0082
[1]CurrentPatentAssignee:HUBEILIVSCIENPHARMSCITECH-CN106366036,2017,A
[2]CurrentPatentAssignee:BEIJINGCHIRALTECHPHARMACEUTICAL-CN104557704,2017,B
[1]CurrentPatentAssignee:HUBEILIVSCIENPHARMSCITECH-CN106366036,2017,A
[1]CurrentPatentAssignee:HUBEILIVSCIENPHARMSCITECH-CN106366036,2017,ALocationinpatent:Paragraph0068
Title: Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis.
Journal: Journal of neuroimmunology 20130515
Title: The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Journal: The Journal of pharmacology and experimental therapeutics 20130201
Title: Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Journal: The Lancet. Oncology 20120701
Title: Pixantrone: a new agent for relapsed aggressive lymphomas.
Journal: The Lancet. Oncology 20120701
Title: Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Journal: Cancer 20111115
Title: Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.
Journal: Expert opinion on drug metabolism & toxicology 20111101
Title: Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.
Journal: Leukemia & lymphoma 20110401
Title: DNA binding by pixantrone.
Journal: Organic & biomolecular chemistry 20101207
Title: New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.
Journal: Journal of medicinal chemistry 20101014
Title: Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
Journal: Expert opinion on pharmacotherapy 20100801
Title: Lymphoma researchers in search of molecular targets.
Journal: Journal of the National Cancer Institute 20100721
Title: Pixantrone maleate for non-Hodgkin's lymphoma.
Journal: Drugs of today (Barcelona, Spain : 1998) 20091101
Title: Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas.
Journal: Future oncology (London, England) 20090501
Title: CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and display antifibrillogenic activity.
Journal: Electrophoresis 20090401
Title: Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets.
Journal: Molecular pharmacology 20080701
Title: Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20080215
Title: Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas.
Journal: Expert opinion on investigational drugs 20071001
Title: Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.
Journal: Investigational new drugs 20070601
Title: Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.
Journal: Nucleic acids research 20070601
Title: A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.
Journal: Leukemia & lymphoma 20070201
Title: EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma.
Journal: Clinical lymphoma & myeloma 20060901
Title: Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis.
Journal: Journal of neuroimmunology 20051101
Title: The role of pixantrone in the treatment of non-Hodgkin's lymphoma.
Journal: Expert opinion on investigational drugs 20050801
Title: Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
Journal: Journal of the neurological sciences 20040815
Title: Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.
Journal: Journal of neuroimmunology 20040601
Title: A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Journal: Expert opinion on pharmacotherapy 20040401
Title: Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
Journal: Haematologica 20030801
Title: Pixantrone (Novuspharma).
Journal: IDrugs : the investigational drugs journal 20030501
Title: Solid-state characterization of a novel chemotherapeutic drug.
Journal: Journal of pharmaceutical sciences 20030301
Title: Characterization of anthracenediones and their photoaffinity analogs.
Journal: Biochemical pharmacology 20020315
Title: Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20010501
Title: A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20010101
Title: Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity.
Journal: Tumori 20010101
Title: Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
Journal: Molecular pharmacology 19950701
Title: Beeharry N, et al. Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biol Ther. 2015;16(9):1397-406.
Title: Hasinoff BB, et al. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform. J Pharmacol Exp Ther. 2016 Feb;356(2):397-409.
Title: Cavalletti E, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007 Jun;25(3):187-95.
Title: Ubiali F, et al. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. J Immunol. 2008 Feb 15;180(4):2696-703.
